We are live on
!
Find out more
ABG
Ally Bridge Group Portfolio holdings
AUM
$124M
1-Year Est. Return
249.88%
This Fund
S&P 500
This Quarter
Est. Return
-2.18%
1 Year Est. Return
+249.88%
3 Year Est. Return
+942.29%
5 Year Est. Return
+671.08%
10 Year Est. Return
–
AUM
$103M
AUM Growth
-$48.7M
(-32%)
Cap. Flow
-$36.6M
Cap. Flow
% of AUM
-35.56%
Top 10 Holdings %
Top 10 Hldgs %
59.56%
Holding
45
New
6
Increased
11
Reduced
10
Closed
15
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Acadia Pharmaceuticals
ACAD
|
+$7.42M |
| 2 |
WHWK
Whitehawk Therapeutics
WHWK
|
+$6.64M |
| 3 |
Cartesian Therapeutics
RNAC
|
+$3.15M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$3.08M |
| 5 |
Atea Pharmaceuticals
AVIR
|
+$3.05M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Sanofi
SNY
|
+$8.74M |
| 2 |
GSK
GSK
|
+$7.5M |
| 3 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$7.08M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
+$6.53M |
| 5 |
Ironwood Pharmaceuticals
IRWD
|
+$4.72M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ultragenyx Pharmaceutical
RARE
$2.88B
| $8.58M | 8.35% |
185,261
-31,814
| -15% | -$1.25M |
|
|
WHWK
2
Whitehawk Therapeutics
WHWK
$192M
| $8.12M | 7.9% |
632,997
+508,372
| +408% | +$6.64M |
|
|
3
Acadia Pharmaceuticals
ACAD
$4.38B
| $7.56M | 7.35% |
+474,741
| New | +$7.42M |
|
|
MRSN
4
DELISTED
Mersana Therapeutics
MRSN
| $6.98M | 6.79% |
47,651
+10,389
| +28% | +$1.76M |
|
|
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| $6.22M | 6.05% |
140,054
+63,565
| +83% | +$2.67M |
|
|
ALLK
6
DELISTED
Allakos
ALLK
| $5.24M | 5.1% |
622,364
+24,192
| +4% | +$168K |
|
|
SGEN
7
DELISTED
Seagen Inc. Common Stock
SGEN
| $4.84M | 4.71% |
37,639
-54,867
| -59% | -$7.08M |
|
|
8
Atea Pharmaceuticals
AVIR
$390M
| $4.63M | 4.5% |
962,694
+602,694
| +167% | +$3.05M |
|
|
SAGE
9
DELISTED
Sage Therapeutics
SAGE
| $4.54M | 4.42% |
119,008
+8,786
| +8% | +$336K |
|
|
AMRN
10
Amarin Corp
AMRN
$292M
| $4.51M | 4.39% |
186,543
-131,371
| -41% | -$3.15M |
|
|
11
Ironwood Pharmaceuticals
IRWD
$635M
| $4.04M | 3.93% |
326,428
-416,142
| -56% | -$4.72M |
|
12
Sana Biotechnology
SANA
$877M
| $4.01M | 3.9% |
1,015,273
+280,023
| +38% | +$1.37M |
|
13
Alkermes
ALKS
$8.79B
| $3.71M | 3.61% |
142,002
-157,998
| -53% | -$3.78M |
|
|
SYRS
14
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $3.12M | 3.03% |
868,403
| – | – |
|
15
Karyopharm Therapeutics
KPTI
$216M
| $3.05M | 2.97% |
59,775
-42,130
| -41% | -$2.92M |
|
16
Nektar Therapeutics
NKTR
$2.31B
| $3.02M | 2.93% |
88,977
+60,114
| +208% | +$2.91M |
|
|
17
Cartesian Therapeutics
RNAC
$243M
| $2.89M | 2.81% |
85,282
+74,140
| +665% | +$3.15M |
|
18
Biohaven
BHVN
$2.32B
| $2.49M | 2.42% |
+179,085
| New | +$2.53M |
|
|
19
Rocket Pharmaceuticals
RCKT
$376M
| $2.45M | 2.38% |
125,176
-354,330
| -74% | -$6.53M |
|
|
MRTX
20
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $2.15M | 2.09% |
+47,520
| New | +$3.08M |
|
21
Repligen
RGEN
$8.31B
| $2.06M | 2.01% |
12,180
-4,544
| -27% | -$824K |
|
|
EPIX
22
DELISTED
ESSA Pharma
EPIX
| $2.05M | 1.99% |
+811,555
| New | +$2.33M |
|
|
MDVL
23
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
| $1.77M | 1.72% |
117,898
| – | – |
|
24
Praxis Precision Medicines
PRAX
$8.77B
| $1.5M | 1.46% |
+42,039
| New | +$1.31M |
|
|
MOR
25
DELISTED
MorphoSys AG American Depositary Shares
MOR
| $1.45M | 1.41% |
405,602
+310,571
| +327% | +$1.39M |
|
Similar funds
MP
EWP
WFA
VWM
EI
TC
IFO
CRW
Ally Bridge Group's Q4 2022 Portfolio in Review
As of Q4 2022, Ally Bridge Group held 45 positions worth $103M, down 32% from $151M the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Ally Bridge Group withdrew a net $36.6M in Q4 2022, closing 15 positions and reducing 10 holdings. Its most notable exit was Sanofi, an estimated $8.74M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
Against the trend, Ally Bridge Group opened a new position in Acadia Pharmaceuticals worth $7.56M.
- Ally Bridge Group's largest Q4 2022 buy was Acadia Pharmaceuticals: 474,741 shares worth $7.56M.
- Ally Bridge Group added most to Whitehawk Therapeutics in Q4 2022, an estimated $6.64M increase.
- Ally Bridge Group's biggest Q4 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $7.08M.
- Ally Bridge Group fully exited Sanofi in Q4 2022, selling an estimated $8.74M.
- Ally Bridge Group's ten largest holdings make up 60% of its $103M portfolio in Q4 2022.
- Ally Bridge Group opened 6 new positions and closed 15 in Q4 2022.
- Ally Bridge Group's portfolio value fell 32% quarter-over-quarter to $103M.
Based on Ally Bridge Group's 13F filing for Q4 2022, filed 14 Feb 2023.